Search Results - Biologics

13 Results Sort By:
Antifungal Small Peptides
­Described are methods and compositions that provide for the production and use of generating synthetic or recombinant peptides having antifungal properties. UTHealth Ref. No.: 2021-0018 Inventors: Dr. Danielle Garsin and Dr. Michael Lorenz Intellectual Property Status: U.S. provisional patent application filed; Available for licensing Associated...
Published: 10/25/2022   |   Inventor(s): Danielle Garsin, Michael Lorenz
Keywords(s):  
Category(s): Biologics, Therapeutics
LGR4 Specific Monoclonal Antibodies and Their Use
­Researchers at UTHealth have isolated and characterized monoclonal antibodies as well as antibody fragments that specifically binding to LGR4, a 7TM receptor that is highly expressed in major types of solid tumors, including but not limited to colorectal cancer, non-small cell lung cancer, and ovarian cancer. These LGR4 specific monoclonal antibodies...
Published: 6/15/2022   |   Inventor(s): Qingyun (Jim) Liu
Keywords(s):  
Category(s): Biologics, Oncology, Therapeutics, Diagnostics, Research Materials
Mutants and Drug Conjugates of R-Spondin Polypeptides for Cancer Therapy
­R-spondins (RSPOs) are secreted proteins with critical roles in cancer development through binding to LGRs and RNF43/ZNRF3 and potentiating Wnt signaling. Various RSPO mutants were discovered that bind to LGRs but no longer function in Wnt signaling. Fc fusion protein of the RSPO mutants, so called RSPO peptibodies, were conjugated with cytotoxic...
Published: 4/29/2022   |   Inventor(s): Qingyun (Jim) Liu
Keywords(s):  
Category(s): Biologics, Oncology, Therapeutics
Novel Oncolytic Herpes Simplex Virus (oHSV) for Cancer Treatment
­ Researchers from UTHealth have developed a novel oncolytic viral therapy, oHSV-shPKR, which can inhibit tumor cells’ antiviral PKR activity, and increase oncolytic virus infection and replication in both oncolytic viral-resistant and sensitive cancer cells. This novel oHSV-shPKR therapy can significantly increase the anti-tumor immune response...
Published: 1/7/2022   |   Inventor(s): Balveen Kaur, BangXing Hong
Keywords(s):  
Category(s): Biologics, Oncology, Therapeutics
Monoclonal Antibodies Against Oncostatin M Receptor (OSMR) for Therapeutic and Diagnostic Use
­Researchers from UTHealth and The Medical College of Wisconsin have collaborated to reveal the role of OSMR in promoting ovarian cancer cell proliferation and metastasis through activation of STAT3 signaling, as well as illuminated the preclinical efficacy of antibody-based OSMR targeting for ovarian cancer treatment. More particularly, researchers...
Published: 12/16/2021   |   Inventor(s): Zhiqiang An
Keywords(s):  
Category(s): Diagnostics, Therapeutics, Biologics, Oncology
Monoclonal Antibodies Against Chitinase 3-like-1 (Chi3l1) for Therapeutic and Diagnostic Use
­Researchers at UTHealth have unveiled a critical role of Chi3l1 in hepatic platelet recruitment during acetaminophen (APAP)-induced liver injury (AILI) using murine models of AILI and concanavalin A (Con A)-induced hepatitis. Significantly, they have developed anti-Chi3l1 monoclonal antibodies and demonstrated the feasibility of targeting CHI3L1...
Published: 12/6/2021   |   Inventor(s): Zhiqiang An, Changqing (Cynthia) Ju
Keywords(s):  
Category(s): Biologics, Therapeutics, Oncology
Monoclonal antibodies against human and mouse leptin for therapeutic and diagonostic use.
BackgroundLeptin is a hormone produced by adipocytes and is elevated in obesity. The congenital lack of leptin results in obesity and the metabolism field widely accepts the concept. Upon cloning of the leptin gene, the original hope was that leptin would act as a break for further food intake and a trigger to increase energy expenditure. The hope was...
Published: 3/5/2020   |   Inventor(s): Zhiqiang An, Philipp Scherer, Ningyan Zhang
Keywords(s):  
Category(s): Biologics, Oncology, Therapeutics, Metabolism
Monoclonal antibodies against human endotrophin for therapeutic and diagonostic use.
Background Studies have shown that endotrophin, the carboxy-terminal cleavage product of the COL6α3 chain, has potent effects on transformed mammary ductal epithelial cells in rodents. It is abundantly expressed in adipose tissue and is a chemoattractant for macrophages, exerts effects on endothelial cells and enhances the progression through...
Published: 1/10/2020   |   Inventor(s): Zhiqiang An, Ningyan Zhang, Philipp Scherer
Keywords(s):  
Category(s): Biologics, Oncology, Therapeutics
Improved Antibody-Drug Conjugate Linker Compositions and Methods of Use
Faculty members at the University of Texas Health Science Center at Houston have developed a novel chemical linker for constructing antibody-drug conjugates (ADCs). While traditional ADC linkers can only load a single payload molecule, the developed linker has the ability to load two identical or different drug payloads. Doubling the number of payloads...
Published: 10/17/2019   |   Inventor(s): Kyoji Tsuchikama, Yasuaki Anami, Chisato Tsuchikama, Zhiqiang An, Ningyan Zhang
Keywords(s):  
Category(s): Research Materials, Oncology, Drug Delivery, Therapeutics, Biologics
Monoclonal Antibodies targeting EpCAM
AbstractEmbodiments of the invention provide high affinity recombinant EpCAM-binding antibodies. Methods of using a such antibodies as imaging agents, diagnostics and therapeutics are also provided. Dual-nuclear and fluorescently labeled or singly fluorescently labeled contrast agents promise the advantage of molecularly-guided surgical resection via...
Published: 10/17/2019   |   Inventor(s): Barrett Harvey, Eva Sevick, Kenneth Pinkston, Ali Azhdarinia
Keywords(s):  
Category(s): Biologics, Research Materials, Oncology, Diagnostics
1 2 
© 2022. All Rights Reserved. Powered by Inteum